• Dr Roy Baynes at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Roy Baynes
    SVP of Head Global Clinical Development, Chief Medical Officer
    Merck Sharp and Dohme (MSD)
  • Dr Robert Deans at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Robert Deans
    CTO
    Blue Rock Therapeutics
  • Dr Ian Hudson at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Ian Hudson
    Chief Executive Officer
    Medicines and Healthcare Products Regulatory Agency
  • Sven Kili at World Advanced Therapies & Regenerative Medicine Congress 2019
    Sven Kili
    Vice President and Head of Gene Therapy Development
    GlaxoSmithKline
  • Jean-Pierre Latere at World Advanced Therapies & Regenerative Medicine Congress 2019
    Jean-Pierre Latere
    COO
    Celyad
  • Ross Macdonald at World Advanced Therapies & Regenerative Medicine Congress 2019
    Ross Macdonald
    Chief Executive Officer
    Cynata Therapeutics Ltd
  • John Maher at World Advanced Therapies & Regenerative Medicine Congress 2019
    John Maher
    Chief Scientific Officer
    Leucid Bio
  • Neill Moray Mackenzie at World Advanced Therapies & Regenerative Medicine Congress 2019
    Neill Moray Mackenzie
    Chairman & Board Mamber
    Cellular Therapeutics Ltd
  • Vivienne Parry at World Advanced Therapies & Regenerative Medicine Congress 2019
    Vivienne Parry
    Head of Engagement
    Genomics England
  • Dr Qasim Rafiq at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Qasim Rafiq
    Associate Professor, Bioprocessing of Cell and Gene Therapies
    University College London
  • Eric Soller at World Advanced Therapies & Regenerative Medicine Congress 2019
    Eric Soller
    Vice President of Corporate Development & Strategy
    BlueRock Therapeutics
  • Dr Frédéric Triebel at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Frédéric Triebel
    Chief Scientific Officer and Medical Officer
    Prima Biomed, Ltd
  • Dr Michael D West, Ph.D. at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Michael D West, Ph.D.
    Chief Executive Officer and Director
    BioTime, Inc.
  • Dr Mark Zimmerman at World Advanced Therapies & Regenerative Medicine Congress 2019
    Dr Mark Zimmerman
    Vice President, Business Development and Strategy
    ViaCyte
1000+
Attendees
500+
Companies
250+
Speakers
80+
Exhibitors
8
Tracks
6
Workshops
 

Pre-Conference

Packed with interactive sessions and targeted networking events the preconference day will include workshops and summits around tailor made to suit your needs and interests in this burgeoning field and allow you to meet the right people easily.
 
Deep dive into topics such as: bioprocessing, logistics, gene editing, investment and AI. Taking place on Wednesday 15th May the new pre-conference day is not to be missed!
 

LEARN MORE

Conference

More interactive panel discussions, roundtables and networking opportunities than ever before! 
 
Targeted tracks divided into specific therapy areas: cell therapy, gene therapy, CAR-T, immune-oncology, tissue engineering andcord blood; including focused tracks on bioprocessing for cell and gene therapy, clinical trials, regulation, pricing and market access as well as a new pitch and partner session for the most exciting company presentations. 
 
The WATRMC is covering every area of advanced therapies in 2019. 

LEARN MORE

Exhibition

The exhibition features more than 60 exhibitors who will showcase the newest tech, software and developments the industry has to offer.
 
In 2019, we are again hosting the Innovation Zone with talks, panels and pitch and partners that could help you develop your business and take your work to the next level.
 

LEARN MORE

Networking

It’s not just about the conference sessions, our Congress recognises the importance of networking.
 
With roundtable discussions, themed networking receptions, networking lunches and our networking app we offer plenty of opportunities to network with your peers and continue conversations in good company.
 

LEARN MORE

 

 

Sign Up for Event Updates

 
 

2019 Advisory Board

 

Sven Kili, Head of Cell & Gene Therapy Development, GSKSven Kili
Head of Cell & Gene Therapy Development
GSK

Bo Kara, Head Process Development, Cell Gene Therapy CMC, GSKBo Kara
Head Process Development, Cell Gene Therapy CMC
GSK

Margo Roberts, Senior VP of Discovery Research, Kite, a Gilead Company Margo Roberts
Senior VP
Discovery Research, Kite, a Gilead Company 

Andre Choulika, CEO, CellectisAndre Choulika
CEO
Cellectis

Eric Soller, Vice President of Corporate Development & Strategy, BlueRock TherapeuticsEric Soller
Vice President of Corporate Development & Strategy
BlueRock Therapeutics

Stephen Badylak, Professor, Department of Surgery, Director, McGowan Center of Pre-Clinical Studies, Deputy Director, McGowan Institute for Regenerative Medicine (MIRM)Stephen Badylak
Professor, Department of Surgery, Director, McGowan Center of Pre-Clinical Studies, Deputy Director, McGowan Institute for Regenerative Medicine ( MIRM )

Robert Beckman, Managing Partner, The Channel Group; Director of Business Development, OrgenesisRobert Beckman
Managing Partner, The Channel Group; Director of Business Development
Orgenesis

Norio Nakatsuji, Professor Emeritus, Kyoto University & Chief Advisor, Stem Cell & Device Laboratory, IncNorio Nakatsuji
Professor Emeritus, Kyoto University & Chief Advisor
Stem Cell & Device Laboratory, Inc

Ohad Karnieli, Chair, Process and Product Development Subcommittee, ISCT; CEO & Co-Founder, ATVIO BiotechnologyOhad Karnieli
Chair, Process and Product Development Subcommittee, ISCT ; CEO & Co-Founder, ATVIO Biotechnology

Steven Pincus, Associate Vice President Virology and Analytical Methods Development, Fujifilm Diosynth BiotechnologySteven Pincus
Associate Vice President Virology and Analytical Methods Development
Fujifilm Diosynth Biotechnology

Claudia Mitchell, Chief Executive Officer, Universal Cells Inc.Claudia Mitchell
Chief Executive Officer
Universal Cells Inc.

Alain Vertès, Managing Director, NxR BiotechnologiesAlain Vertès
Managing Director
NxR Biotechnologies

TBC: Annie Hubert, Director, European Public Policy, Alliance for Regenerative MedicineTBC: Annie Hubert
Director, European Public Policy
Alliance for Regenerative Medicine

TBC: Keith Thompson, CEO, Cell and Gene Therapy CatapultTBC: Keith Thompson
CEO
Cell and Gene Therapy Catapult

 

Companies that attend include

 

 

Advanced Therapies

 

 

 

Cord Blood

 

 

 

 

AI in Healthcare

 

 

 

 

 

Sponsorship packages are tailored to meet your specific business development goals
 

DOWNLOAD PROSPECTUS

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com

See you in London  |  15th - 17th May 2019

 

 

REGISTER NOW

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com